Business
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR)
About this update from Allarity Therapeutics, Inc.
[{"type":"text","content":"Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the special meeting of stockholders on June 20, 2023 (the \"Special Meeting\") was adjourned, without conducting any business, until June 23, 2023 to provide additional time for the Company to obtain approval of the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 6, 2023 (the “Proxy Statement”). The adjourned Special Meeting will reconvene on Friday, June 23, 2023, at 1:00 p.m. (Eastern Time) virtually at https://meetnow.global/MVHUJSD. The record date for the adjourned Special Meeting remains the same, May 30, 2023. Stockholders of record may attend the virtual webcast meeting by logging in through the same method. During this adjournment, the Company will continue to solicit votes from its stockholders regarding all proposals set forth in the Proxy Statement. Stockholders who have already voted their shares on the proposals contained in the Proxy Statement do not need to vote again. Proxies previously submitted will be voted at the adjourned Special Meeting, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Allarity encourages all stockholders, as of the record date on May 30, 2023, who have not yet voted to do so promptly. Stockholders may use the Proxy Card that they were originally provided with or vote in the manner as set forth in the Proxy Statement. Stockholders who have questions or require any assistance in voting their shares may contact the Company at [email protected]. About Allarity Therapeutics Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a clinical-stage pipeline of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatment with doviti...